⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYN News
Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
globenewswire.com
DYN
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
DYN
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
globenewswire.com
DYN
Kohner, Mann & Kailas, S.C., Perkins Coie LLP and Polsinelli PC Announce A Class Action Settlement For Those Who Purchased Natural Gas in Wisconsin Between January 1, 2000 and October 31, 2002
prnewswire.com
AEP
DUK
OKE
EP
CNP
CMS
WMB
XEL
DYN
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
globenewswire.com
DYN
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
globenewswire.com
DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com
DYN
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
globenewswire.com
DYN
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
globenewswire.com
DYN
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
DYN